For the quarter ending 2025-09-30, JAGX made $3,083,000 in revenue. -$9,648,000 in net income. Net profit margin of -312.94%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue, net | 3,083,000 | 2,979,000 | 2,214,000 | 2,930,000 |
| Cost of product revenue | 532,000 | 527,000 | 515,000 | 493,500 |
| Research and development | 3,658,000 | 3,265,000 | 3,730,000 | 4,423,000 |
| Sales and marketing | 1,997,000 | 2,467,000 | 2,493,000 | 2,079,000 |
| General and administrative | 4,134,000 | 4,727,000 | 4,897,000 | 4,120,500 |
| Total operating expenses | 10,321,000 | 10,986,000 | 11,635,000 | 11,116,000 |
| Gain (loss) on extinguishment of debt | - | -1,822,000 | - | 311,250 |
| Loss from operations | -7,238,000 | -8,007,000 | -9,421,000 | -8,186,000 |
| Changes in fair value of freestanding and hybrid financial instruments designated at fair value option | 2,310,000 | 1,068,000 | 1,343,000 | 2,293,000 |
| Interest income (expense) | 6,000 | -15,000 | -56,000 | 250,500 |
| Other income (expense) | -94,000 | 322,000 | 112,000 | 306,000 |
| Loss before income tax expense | -9,648,000 | -10,560,000 | -10,596,000 | -9,801,000 |
| Net loss before equity in net loss of joint venture | - | - | -10,596,000 | - |
| Net loss | -9,648,000 | -10,560,000 | -10,596,000 | -9,801,000 |
| Net loss attributable to noncontrolling interest | - | - | - | -207,666.667 |
| Net loss attributable to common stockholders | - | - | - | -9,666,666.667 |
| Net loss per share, basic | -6.28 | -10.26 | -16.7 | -62.8 |
| Net loss per share, diluted | -6.28 | -10.26 | -16.7 | -62.8 |
| Weighted-average common stock outstanding, basic | 1,513,178 | 1,014,783 | 626,644 | -5,712,516.5 |
| Weighted-average common stock outstanding, diluted | 1,513,178 | 1,014,783 | 626,644 | -5,712,516.5 |
Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc. (JAGX)